Security Advisories

(Latest update: April 3rd, 2024)

Vulnerability

CVE-2023-46604 

Background/Overview

bioMérieux is aware of and out of an abundance of caution is continuing to monitor an authenticated vulnerability for NextGen Mirth^® Connect, a third-party, open-source healthcare data integration platform.  These vulnerabilities impact NextGen Mirth^® Connect 4.4.0 and prior versions. If exploited this vulnerability could allow an attacker to gain unauthorized access to or to compromise data.

After learning of the vulnerability, bioMerieux began conducting investigations of each product to determine if any are affected. These ongoing investigations have determined that while many of our products are not affected, some products do include versions of ActiveMQ^® that are vulnerable. While bioMerieux has no evidence this vulnerability has been exploited on its products or product features, we recommend that customers follow the recommendations sent to them or reach out to your local bioMerieux representative.

 

(Latest update: April 3rd, 2024)

Vulnerability

CVE-2023-43208

Background/Overview

bioMérieux is aware of and out of an abundance of caution is continuing to monitor an authenticated vulnerability for NextGen Mirth^® Connect, a third-party, open-source healthcare data integration platform, 4.4.0 and prior versions. If exploited this vulnerability could allow an attacker to gain unauthorized access to or to compromise data.

After learning of the vulnerability, bioMerieux began conducting investigations of each product to determine if any are affected. These ongoing investigations have determined that while many of our products are not affected, some products do include versions of NextGen Mirth^® Connect that are vulnerable. While bioMerieux has no evidence this vulnerability has been exploited on its products or product features, we recommend that customers follow the recommendations sent to them or reach out to your local bioMerieux representative.

 

(Latest update: March 8th, 2022)

Overview

bioMérieux is aware of, and is monitoring, a set of vulnerabilities, collectively named Access:7, that have recently been disclosed in a third party PTC’s Axeda agent and Axeda Desktop Server that is used by bioMérieux. After learning about the potential vulnerabilities, bioMérieux launched an investigation to determine any potential impact on its products.  

The PTC Axeda agent and Axeda Desktop Server are components of bioMérieux’s VILINK^® with Axeda service, a secure solution offering remote access, proactive maintenance and remote updates. The Axeda agent is a component of VILINK^® solution that is loaded onto bioMérieux computers and uses the TCP port 443 outbound to establish a TLS tunnel with a VILINK^® server.. VILINK^® with Axeda enables support personnel to diagnose and solve software and instrument issues, support systems proactively and keep systems up-to-date. VILINK^® is not a medical device and provides no clinical or industrial diagnostics.  

As further described below, bioMérieux’s investigation to date has determined that its VILINK^® with Axeda is not affected by four of the seven PTC Axeda vulnerabilities. The three remaining vulnerabilities present a low risk to VILINK^® with Axeda.

bioMerieux is continuing to evaluate remediation and controls that eliminate or further reduce any remaining risks, and will update this advisory as necessary.

Please note: VILINK^® with Securelink is not affected by this set of vulnerabilities.

Advisory

The following summarizes each known vulnerability that has been disclosed by  PTC, along with its CVE number, its unadjusted “base” CVSS 3.1 score, and the contextualized environmental CVSS 3.1 score, which takes into account the environmental variables and other risk mitigants that are specific to the VILINK^® with Axeda solution distributed by bioMérieux or its subsidiaries.

Summary Table
(for additional information, see the full CVE descriptions below):

CVE	Applies to VILINK® with Axeda solution	CVSS 3.1 Base Score	CVSS 3.1 Environmental Score
CVE-2022-25251	Yes	9.8	6.4
CVE-2022-25250	Yes	7.5	2.3
CVE-2022-25252	Yes	7.5	2.3
CVE-2022-25246	No	9.8	Not Affected
CVE-2022-25247	No	9.8	Not Affected
CVE-2022-25248	No	5.3	Not Affected
CVE-2022-25249	No	7.5	Not Affected

CVE-2022-25251

Description (Provided by CVE):

xGate and EKernel Read and modify agent configuration: The affected product may allow an attacker to send certain XML messages to a specific port without proper authentication. Successful exploitation of this vulnerability could allow a remote unauthenticated attacker to read and modify the affected product's configuration.

CVSS 3.1 base score: 9.8

Contextualized CVSS 3.1 environmental score: 6.4

AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H/CR:X/IR:X/AR:X/MAV:L/MAC:H/MPR:H/MUI:X/MS:X/MC:X/MI:X/MA:X

bioMérieux Analysis:

The bioMérieux systems have the Windows Firewall activated by default. (Factory setting). TCP Port 3031 is blocked by default through Windows Firewall. Such an exploit would require the threat actor to previously have successfully exploited another vulnerability to gain OS Administrative privileges so as to change the firewall configuration. bioMérieux does not have any indication nor has it been made aware of the existence or exploitation of any such other vulnerability. 

Although this vulnerability is initially rated with a CVSS of 9.8, the complexity of attacks on VILINK^® with Axeda reduces the risk level to low.

However, if the firewall has been disabled or altered from its default state the base CVSS score of 9.8 remains. Please see the recommendations listed below.

CVE-2022-25250

Description (Provided by CVE):

xGate and EKernel, Shut Down: The affected product may allow an attacker to send a certain command to a specific port without authentication. Successful exploitation of this vulnerability could allow a remote unauthenticated attacker to shut down a specific service.

CVSS 3.1 base score: 7.5

Contextualized CVSS 3.1 environmental score: 2.3

AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H/CR:X/IR:X/AR:L/MAV:L/MAC:H/MPR:H/MUI:X/MS:X/MC:X/MI:X/MA:X

bioMérieux Analysis:

The bioMérieux systems have the Windows Firewall activated by default. (Factory setting). TCP Port 3031 is blocked by default through Windows Firewall. Therefore, the risk to the VILINK^® with Axeda service is low.

Further, this CVE presents no risk to any device or system upon which VILINK^® with Axeda is installed.

However, if the firewall has been disabled or altered from its default state the contextualized CVSS environmental score is adjusted to 5.7. Please see the recommendations listed below.

Contextualized CVSS 3.1 environmental score without firewall: 5.7

AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H/CR:X/IR:X/AR:L/MAV:X/MAC:X/MPR:X/MUI:X/MS:X/MC:X/MI:X/MA:X

This environmental score takes into account the low Availability requirement of the VILINK^® with Axeda service on our devices or systems. The VILINK^® with Axeda service unavailability does not affect any device or system’s proper functioning.

CVE-2022-25252

Description (Provided by CVE):

xBase39: The affected product when receiving certain input throws an exception. Services using that function does not handle the exception. Successful exploitation of this vulnerability could allow a remote unauthenticated attacker to crash the affected product.

CVSS 3.1 base score: 7.5

Contextualized CVSS 3.1 score: 2.3

bioMérieux Analysis:

The bioMérieux systems have the Windows Firewall activated by default. (Factory setting). TCP Port 3011 is blocked by default through Windows Firewall. Therefore, the risk to the VILINK^® with Axeda service is low.

Further, this CVE presents no risk to any device or system upon which VILINK^® with Axeda is installed.

However, if the firewall has been disabled or altered from its default state the Contextualized CVSS score is adjusted to 5.7. Please see the recommendations listed below.

Contextualized CVSS 3.1 environmental score without firewall: 5.7

AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H/CR:X/IR:X/AR:L/MAV:X/MAC:X/MPR:X/MUI:X/MS:X/MC:X/MI:X/MA:X

This environmental score takes into account the low Availability requirement of the VILINK^® with Axeda service on our devices or systems. The VILINK^® with Axeda service unavailability does not affect any device or system’s proper functioning.

CVE-2022-25246

Description (Provided by CVE):

AxedaDesktopServer.exe: The affected product uses hardcoded credentials for it's UltraVNC installation. Successful exploitation of this vulnerability could allow a remote authenticated attacker to take full remote control of host operating system via Remote Desktop Connection.

CVSS 3.1 base score: 9.8

bioMérieux Analysis: Not Affected

A generic hardcoded password may allow a threat actor in possession of this password to remotely connect to systems running AxedaDesktopServer (port TCP/5920) in its default configuration. This default configuration is however never used in the context of VILINK^® Agents. 

bioMerieux by design altered the AxedaDeskTopServer.exe configuration and removed the hardcoded credentials.

Additionally VILINK^® with Axeda Agents are configured to either require explicit end-user approval or the presentation of OS user credentials (headless systems) before authorizing any remote sessions.

Therefore, VILINK^® with Axeda is not affected.

CVE-2022-25247

Description (Provided by CVE):

ERemoteServer, System Access: The affected product may allow an attacker to send certain commands to a specific port without authentication. Successful exploitation of this vulnerability could allow a remote unauthenticated attacker to obtain full file-system access and remote code execution.

CVSS 3.1 base score: 9.8

bioMérieux Analysis:  Not Affected

ERemoteServer.exe is never executed in VILINK^® context of use. TCP ports 3076 and 3077 are blocked by the default firewall settings of commercial systems with Windows Firewall enabled.

Therefore, VILINK^® with Axeda is not affected.

CVE-2022-25248

Description (Provided by CVE):

ERemoteServer, Event Text Log: When connecting to a certain port the affected product supplies the event log of the specific service.

CVSS 3.1 base score: 5.3

bioMérieux Analysis: Not Affected

ERemoteServer.exe is never executed in VILINK^® context of use. TCP ports 3076 and 3077 are blocked by the default firewall settings of commercial systems with Windows Firewall enabled

Therefore, VILINK^® with Axeda is not affected.  

CVE-2022-25249

Description (Provided by CVE):

xGate and EKernel, Directory Traversal: The affected product (does not apply to Axeda agent 6.9.2 and 6.9.3) is vulnerable to directory traversal. Which could allow a remote unauthenticated attacker to obtain file system read access via web server

CVSS 3.1 base score: 7.5

bioMérieux Analysis: Not Affected

The vulnerable AxedaWebServer is not embedded in VILINK^® with Axeda. The vulnerability is not present.

Therefore, VILINK^® with Axeda is not affected. 

Recommendations

1. Ensure your firewall is enabled, for more information please see: https://docs.microsoft.com/en-us/windows/security/threat-protection/wind...

2. Check this page periodically for updates
 

 

(Latest update: January 26th, 2022)

Background/Overview

bioMérieux is aware of and currently monitoring vulnerabilities in Apache Log4j. These vulnerabilities potentially allow for unauthenticated remote code execution. Log4j is an open source Java logging library developed by the Apache Foundation widely used in many applications and is present, as a dependency, in many services. bioMérieux is currently investigating to determine whether any products including in its BioFire franchise, are affected and will regularly update this advisory as more information becomes available.

Advisory

bioMérieux has assessed that the following products or product features developed or distributed by bioMérieux or its subsidiaries and determined that they are not running the impacted versions of Log4j disclosed as of the date of this Advisory: 

• 3P^® Software 1.3.3
• APIWEB™ 1.4
• APIWEB™ Standalone
• ASTUTE™
• ATB™ China 2.2.1
• BACT/ALERT^® 3D
• BIOFIRE^® FILMARRAY 2.0
• BIOFIRE^® FILMARRAY TORCH 
• BIOFIRE^® SYNDROMIC TRENDS
• BIOMÉRIEUX EPISEQ^® 16S 1.0
• BIOMÉRIEUX EPISEQ^® CS 1.1
• BIOMÉRIEUX EPISEQ^® SARS-COV-2 1.0
• CLARION™ / AGILIST™
• COPAN Colibrí™
• COPAN C-Tracer
• COPAN WASP^®
• Corepoint Integration Engine
• D-COUNT^®
• easyMAG^® Win10
• EMAG^® SP2
• EVISIGHT^® COMPACT
• LABGUARD^®
• MINI VIDAS^®
• MYLA^® Lab Analytics CLOUD 1.2
• OBSERVA^®
• SCANRDI^®
• SecureLink
• TEMPO^® Routine 
• TEMPO^® Viewer 
• VIDAS^® 3 1.3 and below
• VIDAS^® PC
• VIRTUO^® R2
• VITEK^® 2 8.x and below 

As part of its ongoing investigations, bioMérieux is determining whether other bioMérieux products or product features are running the affected versions of Log4j and testing potential remediation actions if they are. Any remediation actions for potentially exposed bioMérieux products or product features will be made available to customers as soon as possible.

Temporary recommendations

1. When able isolate medical systems on a dedicated network (LAN/VLAN)

a. When isolating the devices follow your local IT governance to ensure required communication is properly secured 

2. Never expose medical devices directly to the internet

“How can you improve the security of network infrastructure devices?

The Cybersecurity and Infrastructure Security Agency (CISA) encourages users and network administrators to implement the following recommendations to better secure their network infrastructure:

• Segment and segregate networks and functions.
• Limit unnecessary lateral communications.
• Harden network devices.
• Secure access to infrastructure devices.
• Perform out-of-band (OoB) network management.
• Validate integrity of hardware and software.”

Source: https://www.cisa.gov/uscert/ncas/tips/ST18-001

General resources

1. General recommendations for Securing Network Devices:

• https://www.cisa.gov/news-events/news/securing-network-infrastructure-devices
• https://www.iso.org/standard/57939.html
• https://www.nist.gov/itl/smallbusinesscyber/guidance-topic/securing-netw...
• https://www.nist.gov/itl/smallbusinesscyber/guidance-topic/securing-data...
• https://www.fda.gov/about-fda/cdrh-patient-science-and-engagement-progra...
• https://www.mitre.org/publications/technical-papers/medical-device-cyber...
• https://www.fda.gov/medical-devices/digital-health-center-excellence/cyb...

​2. General information on Log4j:

• https://www.cisa.gov/uscert/apache-log4j-vulnerability-guidance